Biofrontera Past Earnings Performance

Past criteria checks 0/6

Biofrontera has been growing earnings at an average annual rate of 0.4%, while the Pharmaceuticals industry saw earnings growing at 14% annually. Revenues have been growing at an average rate of 3.3% per year.

Key information

0.4%

Earnings growth rate

6.0%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate3.3%
Return on equity-62.0%
Net Margin-30.1%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Feb 19
We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year

Dec 07
Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year

Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?

Jun 08
Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?

Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 14
Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Revenue & Expenses Breakdown
Beta

How Biofrontera makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XTRA:B8F Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2329-9138
30 Jun 2328-11138
31 Mar 2325-20137
31 Dec 2226-44127
30 Sep 223211187
30 Jun 223110247
31 Mar 223015297
31 Dec 212938347
30 Sep 2128-16286
30 Jun 2127-16295
31 Mar 2129-12265
31 Dec 2030-13285
30 Sep 2033-17335
30 Jun 2033-22375
31 Mar 2031-10455
31 Dec 1931-7445
30 Sep 19261444
30 Jun 19268405
31 Mar 1923-8335
31 Dec 1821-9314
30 Sep 1819-14244
30 Jun 1816-15224
31 Mar 1814-16214
31 Dec 1712-16204
30 Sep 1711-18215
30 Jun 179-16175
31 Mar 178-14145
31 Dec 166-11125
30 Sep 164-994
30 Jun 164-784
31 Mar 164-976
31 Dec 154-1176
30 Sep 154-1277
30 Jun 153-1377
31 Mar 153-1075
31 Dec 143-1175
30 Sep 143-1074
30 Jun 143-1074
31 Mar 143-964
31 Dec 133-853
30 Sep 133-852
30 Jun 133-752
31 Mar 133-542

Quality Earnings: B8F is currently unprofitable.

Growing Profit Margin: B8F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: B8F is unprofitable, but has reduced losses over the past 5 years at a rate of 0.4% per year.

Accelerating Growth: Unable to compare B8F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: B8F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).


Return on Equity

High ROE: B8F has a negative Return on Equity (-61.96%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.